Author

N. P. Kwiatkowski

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Approach:deep learning· 1 Approach:experimental assay· 1 Approach:statistical model· 1

Frequent Co-Authors

H.-S. Seo· 2 shared J. A. Marto· 2 shared S. B. Ficarro· 2 shared S. Dhe-Paganon· 2 shared T. Zhang· 2 shared A. S. Boghossian· 1 shared B. Jiang· 1 shared C. M. Browne· 1 shared

Activity by Year

2019-2022 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

H.-S. Seo

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Covalent Disruptor of YAP-TEAD Association Suppresses Defective Hippo Signaling

M. Fan, W. Lu, J. Che, N. P. Kwiatkowski, Y. Gao, H.-S. Seo, S. B. Ficarro, P. C. Gokhale, Y. Liu, E. A. Geffken, J. Lakhani, K. Song, M. Kuljanin, W. Ji, J. Jiang, , N. Gray

This paper develops a covalent inhibitor of the YAP-TEAD complex, demonstrating its ability to suppress Hippo signaling defects and inhibit cancer cell growth.

bioRxiv · May 10, 2022Cancer Biology

Targeting the PI5P4K lipid kinase family in cancer using novel covalent inhibitors

S. C. Sivakumaren, H. Shim, T. Zhang, F. M. Ferguson, M. R. Lundquist, C. M. Browne, H.-S. Seo, M. N. Paddock, T. D. Manz, B. Jiang, M.-F. Hao, P. Krishnan, D. G. Wang, T. J. Yang, N. P. Kwiatkowski, , N. S. Gray

This study identifies THZ-P1-2, a covalent pan-PI5P4K inhibitor, showing efficacy in AML/ALL cell lines and autophagy disruption, supporting PI5P4Ks as therapeutic targets in cancer.

bioRxiv · Oct 25, 2019Cancer Biology